Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 7712345...102030...Last »

Provention Bio and Johnson & Johnson Ink Deal

Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.

Read More »

Nestle to cut jobs at French skin health R&D center

Nestle plans to cut up to 450 jobs at a Galderma research and development center in southern France, the Swiss company said.

Read More »

Aspen to buy remaining AstraZeneca anesthetic rights

AstraZeneca agreed to sell the U.S. rights to a portfolio of anesthetics to South Africa’s Aspen Group.

Read More »

Otonomy Slashes Staff After Failed Phase III Study

Otonomy is cutting jobs and slashing operations in order to stay in business.

Read More »

J&J Ends Hep C Drug Program

Janssen Sciences Ireland UC, a Johnson & Johnson company, announced the decision to halt development of its hepatitis C treatment combination JNJ-4178.

Read More »

Teva Pharmaceutical Hires New CEO

After six months, Teva Pharmaceutical’s search ended as the company hired a new chief executive officer.

Read More »

Novartis posts a win, Roche a flop in skin cancer trials

Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group.

Read More »

New Mexico sues opioid drug manufacturers, distributors

New Mexico sued eight opioid manufacturers and wholesale distributors, becoming the latest state or local government to file a lawsuit seeking to hold corporations accountable for a national drug addiction epidemic.

Read More »

Lilly Cuts 3,500 Jobs, Shuts Down 2 R&D Sites

Eli Lilly and Company announced the company plans to cut 3,500 jobs. The majority of the job cuts will be in the U.S., and include voluntary early retirement programs.

Read More »

Convert Prior Authorization Abandonments to Rx Fulfillments and Stop Leaving Money on the Table

A very high percentage of Prior Authorization (PA) requests are approved…but about 40% of these prescriptions are abandoned during the PA process, around 74.4 million prescriptions a year.

Read More »

Novartis names new CEO for 2018

Novartis CEO Joe Jimenez will step down on Feb. 1, 2018, and hand over the top leadership role of the Swiss company to drug development chief Vas Narasimhan.

Read More »

Daiichi Sankyo denies AstraZeneca takeover bid

Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.

Read More »

AstraZeneca, Takeda strike Parkinson’s drug deal

AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.

Read More »

AstraZeneca taps AI for drug discovery deal

AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.

Read More »

Gilead Sciences to buy Kite Pharma

Gilead Sciences agreed to buy Kite Pharma in a nearly $12 billion deal as it looks to replace flagging sales from hepatitis C drugs via cancer immunotherapies.

Read More »

CSL Behring Scoops U.S. Biotech Calimmune

CSL Ltd. bought Tucson, Ariz.-based Calimmune for $91 million upfront and up to $325 million in performance-based milestones.

Read More »

Pfizer Picks New HQ in Big Apple

Pfizer reportedly chose a site for the company’s new headquarters, the as-yet constructed Manhattan skyscraper The Spiral.

Read More »

Boston’s Paratek Heads to Auction Block

Shares of Paratek rocketed upward after the antibiotics specialist posted a “for sale” sign on the doors.

Read More »

Argentum, Lilly Settle Cialis Patent Dispute

Argentum Pharmaceuticals announced that it reached a settlement and license agreement with Eli Lilly related to Argentum’s generic version of Cialis (tadalifil).

Read More »

Medtronic misses revenue estimates, shares dip

Medical device maker Medtronic Plc reported Q1 fiscal 2018 revenue fell short of analysts’ estimates, hurt by lower sales in its diabetes-related device business.

Read More »

Page 1 of 7712345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2017 Focus: Pharma Innovators, Top 200 Meds, Lions Health and more!


Ad Right Bottom

Main Navigation